Aimco Pesticides

- Currently, there is no mention of any ongoing or planned fundraising through debt or equity. - The company has put major Capex plans on hold to avoid burdening cash flow during difficult times. - Future Capex decisions, including investments in additional manufacturing capacity, will be taken cautiously after stabilizing profitability and margins. - Any large investments or capacity expansions will be evaluated and decided by the board at appropriate times. - No specific plans for raising funds via equity or debt have been disclosed for FY25 or FY26.

- Current Capex is on hold to avoid burdening cash flow during difficult times; focus is on stabilizing existing business first. - Planned Capex for FY25 includes ₹1.5 to 2 crores to repurpose existing manufacturing facilities for a new product (modification and debottlenecking). - Major Capex proposals (formulation plant and intermediate plant with ~2000 tons capacity) have been deferred to FY26 or beyond, pending profitability and margin improvement. - Two new formulation plants have been acquired; setting up of a new formulation plant expected next year to add capacity, not to shift existing plant. - Additional capacity decisions for three new molecules will be made in Q4 FY25 based on market conditions. - Large-scale capacity expansions for new products anticipated in FY26 after product registrations and market demand improve. - Board to evaluate and approve any major future plant capacity investments carefully.

- Target revenue for FY26: Over ₹210 crore (Ashit Dave on Q4 and FY26 outlook). - Brand business revenue target for FY26: ₹200 crore (aim to double in two years). - Volume growth expectation: 15-20% increase year-on-year. - Export to domestic sales ratio currently ~50:50, with expectation of export business improvement in FY26. - New products: Three recently commercialized molecules expected to generate significant revenue from next financial year. - Capacity utilization: Currently around 70%, with plans to repurpose insecticide plant and consider additional capacity in Q4 FY25. - Bifenthrin capacity to be fully utilized in next two financial years, driven by Brazil market entry. - Overall growth dependent on pricing, market conditions, and regulatory registrations, especially in Brazil. - EBITDA margin expected to remain stable or improve with new high-margin branded products.

- Aimco Pesticides expects to be profitable by the end of FY25, with improving Q3 and Q4 performance. - Revenue target for FY25 is over ₹210 crore, with EBITDA margins expected to improve, though Q4 pricing remains uncertain. - For FY26, a clearer revenue and EBITDA margin target will be shared next quarter; branded business aims for ₹200 crore revenue by FY26. - The company plans 15-20% volume growth annually over the next couple of years, aided by new product launches and export market expansion. - Gross margins for branded formulations are stable at 30-35%, with EBITDA margins around 10%, expected to sustain as product mix improves. - New products commercial ramp-up and export registrations (e.g., Triclopyr in Brazil in FY26) should enhance growth. - Capex remains cautious to preserve cash flow, focusing on repurposing existing plants for new products with major capacity expansions deferred till profitability stabilizes.

- Significant orders are ongoing in Q3, with volume-wise expectations being satisfactory. - Q4 order projections are uncertain due to pricing and supply issues, especially from China. - Negotiations for new export contract products, including a herbicide, are ongoing but not finalized. - Discussions for Bifenthrin volumes in Brazil are active, expecting significant volume in Q4 and full capacity utilization by FY26. - Three new products are commercialized and early stage sales have started; significant ramp-up expected in next financial year. - The company's export orderbook faces pressure from price erosion and competition but volume remains steady. - Domestic brand business order momentum is strong and growing with expected revenue of ₹130 crore for FY25 and ₹200 crore by FY26. - Additional capacity decisions for new molecules pending and to be finalized next quarter.